Abstract: The early diagnosis of diabetic neuropathy (DN) is fundamental in order to enact timely therapeutic strategies for limiting disease progression. In this work, we explored the suitability of ...

Abstract: Magnetic fields switching at kilohertz frequencies induce electric fields in the body, which can cause peripheral nerve stimulation (PNS). Although magnetostimulation has been extensively ...

Diabetic neuropathy is quiet at first. Subtle changes in how your feet feel, how steady you walk, or how your stomach behaves can be the earliest red flags of nerve injury from long-term high blood ...

Doha, Qatar: Specialist physicians from across the globe convened in Doha for a two-day event coordinated by Weill Cornell Medicine-Qatar (WCM-Q) to share the latest best practice on the diagnosis and ...

Objective: To develop a self-reportable risk assessment tool for elderly type 2 diabetes mellitus (T2DM) patients, evaluating risks of diabetic nephropathy (DN), retinopathy (DR), peripheral ...

Abstract: Chronic diabetic wounds represent one of the most prevalent complications of diabetes, often necessitating amputation in severe cases of nonhealing wounds. Cold atmospheric plasma technology ...

Poster #53: Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin Date: September 4, 2025 Time: 4:00 ...

Poster: LX9211, a Novel AAK1 Inhibitor, Alleviates Pain in Preclinical Models of Chemotherapy-induced Neuropathic Pain and Multiple Sclerosis Date: Saturday, September 6, 2025 Time: 8:30 a.m. – 6:00 p ...

THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of ...

Peripheral neuropathy (PN) is a condition characterized by damage to the peripheral nerves, often manifesting as numbness, tingling, burning sensations, or pain in the hands, feet, arms, and legs.

Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results are expected in November ...